Semax and Selank Blend Research: Complementary Neuropeptide Research Tool

The Semax + Selank blend combines two Russian-developed heptapeptides with a shared structural feature but distinct neurochemical targets in a single research preparation. Both peptides contain the Pro-Gly-Pro C-terminal stability extension, but their pharmacological targets are complementary without significant direct overlap — making this blend a useful tool for studying multiple neurochemical systems simultaneously.

Structural Commonality: Pro-Gly-Pro

Despite their different parent peptides, Semax and Selank share an identical C-terminal tripeptide: Pro-Gly-Pro. This was a deliberate design choice by Russian peptide researchers — Pro-Gly-Pro serves as a carboxypeptidase-resistant stability extension that can be appended to different active sequences. Pro-Gly-Pro is itself bioactive (a leukocyte chemotactic factor), adding an additional biological dimension to both peptides.

Mechanistic Complementarity

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) derives from ACTH(4-10) and has been studied primarily in dopaminergic signalling, BDNF expression in hippocampal and cortical models, serotonergic pathway modulation, and neuroprotection in ischaemia research models. Its primary neurochemical focus is monoaminergic and neurotrophin biology.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derives from tuftsin and has been studied primarily in GABAergic signalling, enkephalin degradation inhibition (extending endogenous opioid activity), and immunomodulatory effects. Its primary neurochemical focus is GABAergic and opioidergic biology.

These two systems — monoaminergic/BDNF (Semax) versus GABAergic/opioidergic (Selank) — interact extensively in brain function but are mechanistically distinct enough that simultaneous activation provides complementary rather than redundant coverage.

Research Design Notes

For mechanistic attribution of any observed effect, single-compound control experiments are essential. Signal Labs supplies both Semax and Selank individually. The blend is intended for researchers who want to study the combined neurochemical environment rather than isolate individual pathway contributions.

Published Research References

Neurochemical Systems Covered

The Semax + Selank combination covers the following neurochemical systems relevant to cognitive and neuroprotective research:

Via Semax:

• BDNF/TrkB signalling in hippocampus and prefrontal cortex
• Dopaminergic D1/D2 receptor system modulation in striatum and prefrontal cortex
• Serotonergic 5-HT system modulation
• HIF-1alpha-mediated neuroprotection under ischaemic stress conditions
• NO signalling (Semax influences NOS expression in some research models)

Via Selank:

• GABA-A receptor modulation (anxiolytic pharmacology)
• Enkephalin system through degradation enzyme inhibition
• Tuftsin receptor-mediated immunomodulation (IL-6, interferon-gamma)
• Serotonergic system (some overlap with Semax at this level)

Combined coverage: The combination provides simultaneous neurotrophin (BDNF), monoaminergic (dopamine, serotonin), GABAergic, and opioidergic modulation — a broad multi-system neurochemical research tool in a single preparation.

Assay Selection for Combination Research

BDNF research (primarily Semax-driven): RT-PCR for BDNF mRNA in hippocampal cell models, ELISA for BDNF protein secretion, TrkB phosphorylation by Western blot.

GABAergic research (primarily Selank-driven): Whole-cell patch clamp of GABA-A receptor currents in hippocampal neurons, benzodiazepine site competition binding assays, anxiety-related behaviour paradigms in rodent models.

Combined endpoint research: Synapse density (MAP2/SYN staining), neurite outgrowth assays, cell survival under oxidative or excitotoxic stress — endpoints where both BDNF/neurotrophin effects and GABAergic neuroprotection may contribute simultaneously.

For any combined endpoint where mechanistic attribution is required, parallel single-compound experiments using individual Semax and individual Selank are essential. Signal Labs supplies both individually for this purpose.

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: Semax (individual) | Selank (individual)
View Semax + Selank Blend product and buy →

Pro-Gly-Pro: The Shared Stability Extension

Both Semax and Selank terminate with Pro-Gly-Pro — a tripeptide that provides C-terminal carboxypeptidase resistance. This shared design feature reflects a deliberate strategy in Russian neuropeptide research: appending Pro-Gly-Pro to short bioactive sequences to improve metabolic stability without altering the pharmacological core.

Pro-Gly-Pro provides C-terminal protection because: (1) the terminal Pro is a poor substrate for carboxypeptidase A (which cannot accommodate proline's cyclic side chain in its active site geometry); (2) Gly-Pro is a substrate for prolyl endopeptidase but resistance increases when Pro is at the C-terminus rather than internal; (3) Pro-Gly-Pro itself is independently bioactive and may contribute additional biological properties (leukocyte chemotaxis, MAPK/ERK interactions) not present in the minimal pharmacophore sequences alone.

The consequence for research: the Pro-Gly-Pro extension creates a pharmacological floor of residual biological activity even when the N-terminal pharmacophore sequences are degraded — researchers should be aware that late-timepoint effects in long-duration experiments may reflect Pro-Gly-Pro biology rather than the intended ACTH(4-10) or tuftsin pharmacophore biology.

Cognitive and Neuroprotective Research Context

The combination of Semax and Selank has been studied in the context of cognitive enhancement research in Russian literature, where both compounds are registered pharmaceuticals. The proposed complementary mechanisms — Semax through BDNF/TrkB-mediated synaptic plasticity and dopaminergic circuit modulation, Selank through GABAergic stabilisation and enkephalin preservation — have been framed as addressing both the anabolic (synaptic strengthening, BDNF) and homeostatic (GABAergic stability, anti-anxiety) aspects of cognitive function simultaneously.

Research examining the Semax + Selank combination in cognitive biology uses: hippocampal LTP paradigms (field potential recording in hippocampal slices to measure long-term potentiation as a cellular model of learning), Morris water maze or novel object recognition tasks in rodent models (behavioural endpoints for spatial and recognition memory), and synaptic protein expression (synaptophysin, PSD-95, BDNF by Western blot and ELISA) as molecular endpoints.

Frequently Asked Questions

Why do both Semax and Selank contain Pro-Gly-Pro if they have different parent peptides?
The Pro-Gly-Pro extension was deliberately added to both sequences as a shared stability strategy. The research programme at the Institute of Molecular Genetics in Moscow, which developed both compounds, identified Pro-Gly-Pro as an effective and biologically tolerable stability extension applicable to multiple short neuropeptide sequences. The extension was appended to ACTH(4-10) to produce Semax, and to the tuftsin-derived sequence to produce Selank, as a systematic approach to improving the research utility of both parent sequences. This shared design strategy makes the two compounds mechanistically similar in terms of metabolic stability while retaining distinct N-terminal pharmacophores targeting different receptor systems.

Are there published clinical studies examining Semax and Selank in combination?
Published clinical research on the Semax + Selank combination is limited primarily to Russian-language literature and small clinical studies conducted within the Russian pharmaceutical registration framework. The most commonly cited clinical application is anxiety-asthenic disorders, where the anxiolytic properties of Selank combined with the cognitive and neuroprotective properties of Semax are proposed to provide complementary clinical benefits. For laboratory research purposes, Signal Labs supplies both compounds individually and as the blend; the research literature on each compound separately is substantially more extensive than the combination research, and individual compound studies should be used as the primary mechanistic reference.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide

Semax + Selank Blend: Reconstitution and Working Concentration Guide

The Semax + Selank blend contains 10mg of each component (20mg total) in a single lyophilised vial. Because the two components have different molecular weights — Semax (MW approximately 887 g/mol) and Selank (MW approximately 863 g/mol) — the molar content of each component at any given mass reconstitution is approximately equal but not identical:

At 1mg/mL total concentration (20mL reconstitution): Each component is at 0.5mg/mL. Semax 0.5mg/mL = approximately 564 microM; Selank 0.5mg/mL = approximately 579 microM. Working concentrations of 100 nM - 10 microM for each component are achieved by serial dilution of this stock.

For matched molar concentration: To have exactly equal molar concentrations of both components, the reconstitution volume needs minor adjustment based on the MW ratio (Semax 887 / Selank 863 = 1.028). In practice, the approximately 3% MW difference is negligible for most research designs and can be ignored.

Individual compound reference: The nominal concentration of each component in the blend can be verified against Single-compound dose-response curves using individually purchased Semax and Selank. If a 1 microM Semax solution produces effect X in your assay, and the blend at 1 microM total (0.5 microM each) produces a different effect, this difference characterises the contribution of the combined environment versus individual pharmacology.